Imiquimod and Sumatriptan drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Imiquimod (imiquimod) and Sumatriptan (sumatriptan succinate). Common drug interactions include application site erythema among females and anhedonia among males.

The phase IV clinical study analyzes what interactions people have when they take Imiquimod and Sumatriptan. It is created by eHealthMe based on reports of 13 people who take the same drugs from the FDA, and is updated regularly.

What is Imiquimod?

Imiquimod has active ingredients of imiquimod. eHealthMe is studying from 2,038 Imiquimod users. Check the latest studies of Imiquimod.

What is Sumatriptan?

Sumatriptan has active ingredients of sumatriptan succinate. It is often used in migraine. eHealthMe is studying from 18,159 Sumatriptan users. Check the latest studies of Sumatriptan.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.



On Sep, 04, 2026

13 people who take Imiquimod and Sumatriptan together, and have interactions are studied.

Imiquimod and Sumatriptan drug interactions.

What are the common drug interactions of Imiquimod and Sumatriptan, by gender? *:

female:

  1. Application site erythema (redness of the skin at application site)
  2. Drug ineffective
  3. Death
  4. Surgery
  5. Back pain
  6. Cystitis (inflammation of the wall of the bladder)
  7. Injection site pruritus (severe itching at injection site)
  8. Injection site rash
  9. Muscle spasms (muscle contraction)
  10. Muscle tightness

male:

  1. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  2. Anxiety
  3. Methaemoglobinaemia (a disorder characterized by the presence of a higher than normal level of methemoglobin in blood)
  4. Middle insomnia (difficulty returning to sleep after awakening either in the middle of the night)
  5. Monocyte count increased
  6. Multiple fractures
  7. Osteopenia (a condition where bone mineral density is lower than normal)
  8. Osteoporosis (bones weak and more likely to break)
  9. Oxygen saturation increased
  10. Pain

What are the common drug interactions of Imiquimod and Sumatriptan, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  2. Anxiety
  3. Asthma
  4. Blood bicarbonate decreased
  5. Blood ph increased
  6. Bone density decreased
  7. Dyspnoea (difficult or laboured respiration)
  8. Emotional distress
  9. Haemoglobin decreased
  10. Mean platelet volume increased (more than normal average size of platelet cells in blood)

50-59:

  1. Pain
  2. Pain in extremity
  3. Urinary tract infection
  4. Back pain
  5. Injection site pruritus (severe itching at injection site)
  6. Injection site rash
  7. Muscle spasms (muscle contraction)
  8. Muscle tightness
  9. Musculoskeletal pain (pain affects the bones, muscles, ligaments, tendons, and nerves)
  10. Musculoskeletal stiffness (stiffness of the body's muscles, joints, tendons, ligaments and nerves)

60+:

  1. Application site erythema (redness of the skin at application site)
  2. Drug ineffective
  3. Death

What are the existing conditions these people have? *

  1. Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 3 people, 23.08%
  2. Hypersensitivity: 3 people, 23.08%
  3. Hiv Infection: 3 people, 23.08%
  4. Asthma: 3 people, 23.08%
  5. Hypertensive Emergency: 2 people, 15.38%
  6. Precancerous Skin Lesion: 1 person, 7.69%
  7. Juvenile Rheumatoid Arthritis (joint inflammation in children due to systemic disease): 1 person, 7.69%
  8. Headache (pain in head): 1 person, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Imiquimod and Sumatriptan?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Imiquimod and Sumatriptan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Imiquimod:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Sumatriptan:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Imiquimod and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Sumatriptan and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on imiquimod and sumatriptan succinate (the active ingredients of Imiquimod and Sumatriptan, respectively), and Imiquimod and Sumatriptan (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: